Evidence Level
Rhodiola Rosea has been studied in several randomized controlled trials (RCTs) and smaller clinical studies, with a growing body of evidence supporting its use for managing stress-related fatigue and enhancing cognitive performance. Research typically uses extracts standardized to 3% rosavins and 1% salidroside, with doses ranging from 200-600mg daily. A notable multicenter RCT (n=161) demonstrated significant reductions in fatigue and improvements in memory and associative thinking during stressful conditions compared to placebo. While more research is needed for long-term effects and broader applications, the existing evidence suggests moderate efficacy for stress-related fatigue and cognitive support under acute stress.